GIGABYTE
21.5.2024 03:01:30 CEST | Business Wire | Press release
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products poised to define the AI era.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240517872510/en/
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On (Graphic: Business Wire)
Building on last year’s success, GIGABYTE looks to solidify its AI leadership with the theme “ACCEVOLUTION,” reflecting the increasing demand for computing and GIGABYTE’s ability to “accelerate the next evolution.” With its largest-ever presence at COMPUTEX, GIGABYTE’s booth stands as the largest single-brand exhibit. Showcasing a wide range of products, solutions, and applications aligned with the AI trend, GIGABYTE covers key tech trends including AI computing, advanced connectivity, future mobility, immersive reality, sustainability, and innovation.
GIGABYTE’s remarkable advancements in AI server development in recent years have garnered widespread attention, as GIGABYTE introduced the G593-SD0, the world’s first and only NVIDIA-certified 5U AI server to efficiently support the HGX™ H100 8 x SXM5. GIGABYTE further expands its super AI server lineup with ARM-based AI servers featuring the next-generation Grace Hopper™ superchip, and AI servers supporting AMD’s next-gen superchips MI300X GPU and MI300A APU. This year, on top of the upgraded H200 GPU, with NVIDIA unveiling the Blackwell architecture, GIGABYTE will showcase ahead of schedule at its booth the latest high-density servers compatible with GPUs such as B100 and B200. The highly-anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as GB200 NVL72, acting as one massive GPU that can achieve 30 times the inference performance of the same amount of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions with professionals about the future of AI development and computing deployment.
As AI becomes ubiquitous, computing demand rises sharply in large data centers and AI startups. At this year’s COMPUTEX, GIGABYTE presents GIGA POD, a scalable rack integration solution, designed to meet data center-level deployments. Beyond showing GIGA POD’s comprehensive hardware and software integration and AI training optimization environments, on-site demonstrations will highlight its performance leadership and deployment flexibility.
GIGABYTE’s AI development encompasses GPU parallel computing, data storage, and network transmission in data centers. GIGABYTE’s R&D prowess is evident in industry-leading thermal and mechanical design, while modular design enables product diversity, speeding up time-to-market. At the booth, find servers for cloud to edge computing, high-performance to high-density storage, and computing options for SMBs and micro-enterprises, including DIY server motherboards tailored to AI development at various scales.
GIGABYTE’s green computing complements AI advancements perfectly. Innovations like Direct Liquid Cooling and Immersion Cooling redefine performance and efficiency, offering comprehensive setups for servers and cabinets. This enables servers with the latest chips from AMD, Intel, and NVIDIA to surpass traditional cooling limits, enhancing heat dissipation and computational density while ensuring stability. GIGABYTE’s sustainability commitment is evident in immersion cooling solutions, supporting technological advancements with optimal power usage.
GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.
In the consumer PC market, GIGABYTE leads with AI-enhanced products like motherboards, graphics cards, and AI gaming laptops. These feature stable AI computing power and innovative capabilities such as the AI Nexus in the AORUS 16X gaming laptop, offering applications like AI Power Gear and AI Boost. At our booth’s AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.
GIGABYTE is bringing an impressive products portfolio to COMPUTEX, demonstrating its capacity to accelerate the next evolution of technology in this changing AI landscape, and its abundance of computing solutions driven by the connectivity and velocity of data and AI can elevate businesses and empower individuals to thrive in the extra-fast growing and development time.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240517872510/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom